The launch marks Aurobindo Pharma's entry into the US inhalation market and expands its complex generics portfolio beyond conventional oral solid formulations
Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana. In May this year the company had stated that the US Food and Drug Administration (USFDA) inspected Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities Ltd located at Telangana from February 16 to February 27, 2026. The inspection had concluded with four observations and the USFDA had determined the facility as 'official action indicated' (OAI). "Subsequent to OAI, the unit has received a warning letter," Aurobindo Pharma said in a regulatory filing. There is no impact on the existing supplies to the US markets, it added. The company further said the Unit I of Eugia Pharma Specialities Ltd, is contributing to about 2 per cent to company's overall group revenue. Aurobindo Pharma said it remains committed to working closely with the US FDA and continues to enhance its compliance on a
Only a breach below 24,000 will weaken the structure; otherwise, intraday dips toward the support zone of 24,150-24,180 should be used as a buying opportunity, said Jatin Gedia.
Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.
In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.
Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.
Stocks to Watch today, June 29: Tata Motors PV, Torrent Power, Dr Reddy's Laboratories, Aurobindo Pharma, KEC International, and Adani Ports are among the top stocks to watch during today's trade
Market outlook by Ajit Mishra: The analyst from Religare Broking expects Nifty to consolidate in the near-term; among stocks he recommends Delhivery, Ather Energy and Aurobindo Pharma.
Aurobindo Pharma on Monday said its arm Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. The transaction, valued at USD 250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of this month, Aurobindo Pharma said in a regulatory filing. Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances, the filing said. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network, it added. "This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position i
Aurobindo Pharma received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.
Stocks to Watch today, May 25, 2026: Shares of oil marketing companies will remain in focus today after petrol and diesel prices were raised by ₹2.61-2.71 per litre on Monday
Aurobindo Pharma Q4 results 2026: Aurobindo Pharma has reported a 2 per cent rise in consolidated profit after tax to ₹920.84 crore in the fourth quarter ended March 31.
Stocks to Watch today, May 22, 2026: Nykaa, LIC, ITC, Honasa Consumer, and Maruti Suzuki are some of the key stocks to watch today
The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk
Nandish Shah of HDFC Securities has shared a Bear Spread strategy on Nifty, and a Bull Spread strategy on Aurobindo Pharma.
Stock picks: Ajit Mishra of Religare Broking recommends buying Aurobindo Pharma, Tata Steel & Sona BLW; here's why
The Nifty Midcap Select index hit a new high of 14,223.90, soaring 2% and surpassing its previous high of 14,118 touched on December 1, 2025.
Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements
Notably, Indian equity markets will remain closed on Tuesday, April 14, on account of Dr Baba Saheb Ambedkar Jayanti.
Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today